WO2026001964 - KRAS INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/001964
Publication Date
02.01.2026
International Application No.
PCT/CN2025/103068
International Filing Date
24.06.2025
Title **
[English]
KRAS INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
[French]
COMPOSÉ INHIBITEUR DE KRAS, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES
[Chinese]
KRAS抑制剂化合物、其药物组合物及其用途
Applicants **
SUNSHINE LAKE PHARMA CO., LTD.
Inventors
LIU, Haiwang
XIE, Hongming
FENG, Xihui
LUO, Guolin
ZHANG, Yingjun
Priority Data
202410829476.X
25.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2724 | |
| EPO | Filing, Examination, Granting | 18229 | |
| Japan | Filing, Examination, Granting | 2370 | |
| South Korea | Filing, Examination, Granting | 2596 | |
| USA | Filing, Examination, Granting | 5590 |
Total:
31,509
Contact Us
Abstract[English]
The present invention relates to the technical field of medicine. Specifically, the present invention relates to a KRAS inhibitor compound, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the compound as represented by formula (I). The compound and the pharmaceutical composition thereof provided in the present invention can be used for preparing medicaments for preventing or treating diseases related to KRAS amplification or mutations such as KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, or KRAS Q61H, and can especially be used for preparing medicaments for preventing or treating cancer.[French]
La présente invention se rapporte au domaine technique de la médecine. En particulier, la présente invention concerne un composé inhibiteur de KRAS, une composition pharmaceutique et une utilisation associées. Plus particulièrement, la présente invention concerne un composé tel que représenté par la formule (I), ou un stéréoisomère, un tautomère, un oxyde d'azote, un solvate, un métabolite, un sel pharmaceutiquement acceptable ou un promédicament du composé représenté par la formule (I). Le composé et la composition pharmaceutique de celui-ci selon la présente invention peuvent être utilisés pour préparer des médicaments pour prévenir ou traiter des maladies associées à l'amplification ou des mutations de KRAS telles que KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, ou KRAS Q61H, et peuvent notamment être utilisés pour préparer des médicaments pour la prévention ou le traitement du cancer.[Chinese]
本发明属于药物技术领域，具体地，本发明涉及一种KRAS抑制剂化合物、其药物组合物及其用途。具体地，本发明涉及式(I)所示化合物，或式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或前药。本发明涉及的化合物及其药物组合物可用于制备用于预防或治疗与KRAS扩增型或KRAS G12A、KRAS G12C、KRAS G12D、KRAS G12R、KRAS G12S、KRAS G12V、KRAS G13D或KRAS Q61H等突变相关的疾病的药物，尤其可用于制备用于预防或治疗癌症的药物。